IP Library Granted Patent US 10,301,629
Granted Patent B2
US 10,301,629 · App. 14/897,450 · Granted May 28, 2019

Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides

Inventors: Bruce H. Littman (Stonington, CT); John F. Thompson (Warwick, RI); Frank W. Marcoux (Stonington, CT)
Assignee: PORTAGE PHARMACEUTICALS LTD.
C12N15/1137A61K38/1709A61K38/45A61K38/465A61K38/47A61K38/482A61K38/51A61K39/05A61K47/645C07K14/4702C12N9/12C12N9/16C12N9/2402C12N9/6424C12N9/88C07K2319/01C07K2319/10C12N2310/3513C12Y207/1101C12Y301/06013C12Y302/01045C12Y302/01076C12Y304/21093C12Y406/01002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,301,629
App. No.
14/897,450
Granted
May 28, 2019
Kind
B2
Abstract

Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS. In various embodiments, the disclosed compositions are suitable for delivery into a cell (i) the expression product of a gene of interest and/or (ii) novel peptides or polynucleotides to regulate gene function.

Claims (3)

1. A cell-penetrating peptide conjugate consisting of SEQ ID No. 22.

2. The conjugate of claim 1 wherein the conjugate interacts with an intracellular target and/or an intranuclear target.

3. A composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.

Assignments (2)
CHANGE OF NAME Recorded May 28, 2021
From: PORTAGE PHARMACEUTICALS LTD.
To: PPL (BVI) LIMITED
Reel/Frame 056380/0541 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2016
From: LITTMAN, BRUCE H.; THOMPSON, JOHN F.; MARCOUX, FRANK W.
To: PORTAGE PHARMACEUTICALS LTD.
Reel/Frame 039096/0659 →
Continuity (2)
Provisional Application 61833819 · Jun 11, 2013
Related Publication 20160136293A1 · May 19, 2016
Cited By (1)
US 12,214,007